SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs
12 references·1 citing·38 second hop
Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs (2014)Medicines for the Mind: Policy-Based “Pul…The view beyond venture capital (2014)The view beyond venture capit…Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)Drug discovery in pharmaceuti…Cost of disorders of the brain in Europe 2010 (2011)Cost of disorders of the brai…Accelerated Approval of Oncology Products: The Food and Drug Administration Experience (2011)Accelerated Approval of Oncol…Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)Trends in Risks Associated Wi…Is Pharma Running Out of Brainy Ideas? (2010)Is Pharma Running Out of Brai…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Drug development costs when financial risk is measured using the Fama–French three‐factor model (2009)Drug development costs when f…Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs? (2009)Accelerated Approval of Cance…The State of Innovation in Drug Development (2008)The State of Innovation in Dr…A Note on Economic Losses Due to Theft, Infringement, and Piracy of Protected Works (2004)A Note on Economic Losses Due…Translating a rodent measure of negative bias into humans: the impact of induced anxiety and unmedicated mood and anxiety disorders (2019)Translating a rodent measure …Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The price of innovation: new estimates of drug development costs (2003)The black swan: the impact of the highly improbable (2007)The productivity crisis in pharmaceutical R&D (2011)THE WORLD MEDICINES SITUATION 2011 (2011)Can the pharmaceutical industry reduce attrition rates? (2004)Into the valley of death: research to innovation (2013)The changing model of big pharma: impact of key trends (2015)Exploring the impact of open innovation on firm performances (2016)Common risk factors in the returns on stocks and bonds (1993)The theory and practice of corporate finance: evidence from the field (2001)Market spiral pricing of cancer drugs (2013)Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)R&D Costs of New Medicines: A Landscape Analysis (2021)Comprehensive Textbook of Psychiatry (1967)Comprehensive Textbook of Psychiatry (1968)The size and burden of mental disorders and other disorders of the brain in Europe 2010 (2011)The association between social relationships and depression: A systematic review (2015)Scaling-up treatment of depression and anxiety: a global return on investment analysis (2016)Sleep, insomnia, and depression (2019)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Deconstructing the Drug Development Process: The New Face of Innovation (2010)Challenges and opportunities of drug repositioning (2013)Killer Acquisitions (2020)Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development (2018)Rodent models of post-traumatic stress disorder: behavioral assessment (2020)Putting the “mental” back in “mental disorders”: a perspective from research on fear and anxiety (2022)Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019 (2022)Cardiovascular Drug Development (2015)Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study (2015)Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration (2017)Translation of rare disease research into orphan drug development: disease matters (2009)An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011 (2013)Behavioral profiling as a translational approach in an animal model of posttraumatic stress disorder (2016)
this work references cited by second hop

References

  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2011Cost of disorders of the brain in Europe 20101,720 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2010Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs847 cited
  • 2012Drug discovery in pharmaceutical industry: productivity challenges and trends478 cited
  • 2010Is Pharma Running Out of Brainy Ideas?284 cited
  • 2008The State of Innovation in Drug Development276 cited
  • 2011Accelerated Approval of Oncology Products: The Food and Drug Administration Experience212 cited
  • 2009Drug development costs when financial risk is measured using the Fama–French three‐factor model108 cited
  • 2009Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?85 cited
  • 2014The view beyond venture capital36 cited
  • 2004A Note on Economic Losses Due to Theft, Infringement, and Piracy of Protected Works17 cited

Cited by

  • 2019Translating a rodent measure of negative bias into humans: the impact of induced anxiety and unmedicated mood and anxiety disorders49 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work